Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIONA OLE finerenone long-term safety extension in pediatric chronic kidney disease with proteinuria
2023-504885-50-00Phase 3Authorised
- Sponsor
- Bayer
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 32
01
Overview
Phase 3, open-label, single-arm trial of finerenone in chronic kidney disease (CKD), sponsored by Bayer. Primary endpoints: Treatment-emergent adverse events, Change in serum potassium and 1 more. Planned start Nov 2022; status: authorised.
02
Drugs
finerenone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2023-504885-50-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504885-50-00.